Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
Halozyme Therapeutics, Inc. (HALO) had Receiveable Turnover of 3.17 for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$1.40B |
|
$316.89M |
|
$228.77M |
|
$1.17B |
|
$927.60M |
|
$469.01M |
|
$-2.13M |
|
$466.88M |
|
$466.88M |
|
$316.89M |
|
$316.89M |
|
$316.89M |
|
$316.89M |
|
$469.01M |
|
$561.27M |
|
119.84M |
|
123.90M |
|
$2.64 |
|
$2.56 |
|
| Balance Sheet Financials | |
$825.21M |
|
$82.14M |
|
$1.70B |
|
$2.53B |
|
$177.09M |
|
$2.14B |
|
$2.30B |
|
$2.48B |
|
$48.81M |
|
$-1.51B |
|
$48.81M |
|
117.78M |
|
| Cash Flow Statement Financials | |
$651.56M |
|
$-545.81M |
|
$-85.17M |
|
$115.85M |
|
$136.42M |
|
$20.57M |
|
$51.56M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.66 |
|
-- |
|
-- |
|
0.98 |
|
43.89 |
|
83.62% |
|
33.58% |
|
33.58% |
|
40.19% |
|
33.43% |
|
22.69% |
|
$644.59M |
|
-- |
|
-- |
|
-- |
|
0.55 |
|
1.30 |
|
|
Receiveable Turnover |
3.17 |
115.33 |
|
649.18% |
|
-20.94% |
|
12.55% |
|
14.46% |
|
$0.41 |
|
$5.20 |
|
$5.26 |
|